Biopharma AI
By
Can Receptor.AI’s Integration of REAXENSE™ Platform Redefine Full-Stack Drug Discovery?
Key Insights: Advanced Chemistry at ScaleReceptor.AI has incorporated the REAXENSE™ platform, developed by Canada-based Reaxense Inc., into its…
How Are NUS and UC San Diego Using AI to Unlock Sex-Specific Drug Combos for Aortic Valve Disease?
Key Highlights: AI-Powered Personalization: Unlocking Sex-Specific Drug EfficacyThe collaboration between the National University of Singapore’s WisDM and UC…
Will XtalPi’s AI-Driven Acquisition of LCC Redraw the Map of Chiral Drug Discovery?
Key Highlights: AI Meets Chiral Chemistry in Strategic UK AcquisitionXtalPi Holdings Ltd. (HKEX: 2228), the AI-powered drug discovery…
Is DeepCure’s AI-Designed Oral STAT6 Inhibitor the Next Breakthrough in Atopic Dermatitis Treatment?
Key Highlights: Oral Option for Dupilumab-Class PatientsDeepCure’s newly nominated candidate DC-15442 offers a breakthrough alternative to injectable biologics…
Can Lisata Therapeutics and GATC Health’s AI Breakthrough Redefine Drug Discovery and Tackle the Opioid Crisis in Just One Year?
Key Highlights AI-Powered Drug Discovery Moves Toward the Clinic with OUD FocusLisata Therapeutics and GATC Health have expanded…
Is Merck’s $10B Acquisition of Verona a Strategic Masterstroke to Offset Keytruda’s Patent Cliff and Dominate the $30B+ Respiratory Market?
Key Highlights Merck Secures Verona to Bridge Its Post-Keytruda Future Merck & Co. has taken a bold step…
